FDA
-
-
-
-
-
-
-
Adamas Named 2021 Finalist in the New Therapeutics Category of the UCSF Health Awards
-
-
-
-
-
-
-
New Data Analysis Supports GOCOVRI as an Important Treatment for Motor Complications for People With Parkinson’s Disease
-
-
-
-
-
-
-
Adamas Pharma (ADMS) Announces FDA Approval for Second Indication for GOCOVRI as Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes
-
-
-
-
-
-
-
Adamas Announces Agreement to Amend Royalty-Backed Loan Agreement with HealthCare Royalty Partners
-
-
-
-
-
-
-
Adamas to Present at Upcoming HC Wainwright Conference
-
-
-
-
-
-
-
Pre-Open Stock Movers 06/18: (ALPN) (AEMD) (ELOX) Higher; (LPTX) (QUIK) (BIIB) Lower (more...)
-
-
-
-
-
-
-
Adamas announces FDA filing acceptance of sNDA to modify the indication statement for GOCOVRI® to include treatment for Parkinson’s disease patients receiving levodopa and experiencing OFF episodes
-
251,398 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All